IPG Investment Advisors LLC Makes New Investment in Illumina, Inc. $ILMN

IPG Investment Advisors LLC acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 8,691 shares of the life sciences company’s stock, valued at approximately $2,379,000.

Several other large investors also recently added to or reduced their stakes in ILMN. Fiduciary Financial Advisors purchased a new position in Illumina during the second quarter worth about $26,000. MCF Advisors LLC raised its holdings in shares of Illumina by 172.4% in the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 100 shares in the last quarter. Keating Financial Advisory Services Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at about $32,000. Rakuten Securities Inc. purchased a new stake in shares of Illumina in the 2nd quarter valued at about $33,000. Finally, WealthCollab LLC boosted its position in shares of Illumina by 51.5% during the 1st quarter. WealthCollab LLC now owns 303 shares of the life sciences company’s stock valued at $37,000 after acquiring an additional 103 shares during the last quarter. Institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

ILMN opened at $238.21 on Wednesday. The stock has a 50-day moving average price of $249.74 and a 200-day moving average price of $177.05. Illumina, Inc. has a 12-month low of $112.65 and a 12-month high of $309.35. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $36.02 billion, a P/E ratio of 43.16, a PEG ratio of 3.08 and a beta of 1.46.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 EPS for the quarter, beating the consensus estimate of $1.36 by $0.26. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company’s revenue was up 4.2% on a year-over-year basis. During the same period in the prior year, the company earned $1.34 EPS. Equities analysts predict that Illumina, Inc. will post 5.43 earnings per share for the current fiscal year.

Insider Activity at Illumina

In other Illumina news, Director Keith A. Meister sold 119,501 shares of Illumina stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the transaction, the director directly owned 770,350 shares of the company’s stock, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Christensen Wedel sold 1,033 shares of Illumina stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president directly owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 1,320,108 shares of company stock valued at $288,195,392. 2.90% of the stock is owned by insiders.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina was selected to provide whole-genome sequencing services for Singapore’s SG-INSIGHT study, expected to cover about 450,000 people—roughly one in 10 residents. The project extends the company’s work in Singapore into broader clinical and public-health applications, offering a significant showcase for precision medicine. Article
• Neutral Sentiment: The large population covered by the study could create strategic opportunities, but no contract value, revenue timing, or sequencing volume for Illumina was disclosed, so the near-term financial impact is uncertain. Article
• Negative Sentiment: Citigroup raised its price target for ILMN but maintained a “sell” rating, indicating it still sees potential downside. Separately, commentary on the Q3 call cited persistent weakness in research and applied markets, despite strength in clinical sequencing and NovaSeq X placements. Article Article

Wall Street Analyst Weigh In

ILMN has been the subject of several recent analyst reports. TD Cowen boosted their price objective on Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Weiss Ratings upgraded shares of Illumina from a “hold (c)” rating to a “buy (b-)” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a research note on Wednesday, August 5th. UBS Group upgraded shares of Illumina from a “neutral” rating to a “buy” rating and lifted their target price for the company from $135.00 to $260.00 in a research report on Wednesday, September 9th. Finally, Piper Sandler lifted their target price on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Illumina has an average rating of “Hold” and a consensus target price of $244.24.

Illumina Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.